Androcur patients will have to attest that they are informed of the risks of tumor - the obs
Dès le 1er juillet, tout patient débutant un traitement avec Androcur ou ses génériques devra être informé du risque de tumeur lié à ces médicaments et bénéficier d’un examen d’imagerie cérébrale, selon l’Agence du médicament.
« Cette information concerne principalement les femmes, l’acétate de cyprotérone, principe actif de ces médicaments, étant minoritairement prescrit aux hommes, notamment pour le cancer de prostate et les déviances sexuelles (castration chimique pour pédophilie et/ou viols à répétition) », explique à l’AFP le Dr Jean-Michel Race, endocrinologue, de l’ANSM.
An information sheet on the risk of meningioma (most often benign tumor) of these drugs must now be given by prescribing doctors to their patients.
The latter will only be able to obtain these drugs in pharmacy on the compulsory presentation of an annual information certificate that they have signed as well as the prescribing doctor, from July 1 for new treatments and January 1, 2020 for renewals.
Intracranial tumors
The Androcur (Bayer Laboratory) and its generics prescribed to combat severe excessive hair (hirsutism) or, out of its official indication, for endometriosis or acne, can multiply up to 20 (after 5 years of treatment), and even more, the probability of intracranial tumors in women treated for a long time and high doses.
Find other articles from Amavea here
